Labcorp price target lowered to $235 from $260 at Citi

Citi analyst Patrick Donnelly lowered the firm’s price target on Labcorp to $235 from $260 and keeps a Neutral rating on the shares. The analyst reduced estimates post the Q1 report to reflect softening Drug Discovery results.